Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.

Jönsson F, Hagedorn C, Kreppel F.

J Vis Exp. 2018 Oct 26;(140). doi: 10.3791/58480.

PMID:
30417881
2.

Production, Purification, and Titration of First-Generation Adenovirus Vectors.

Kratzer RF, Kreppel F.

Methods Mol Biol. 2017;1654:377-388. doi: 10.1007/978-1-4939-7231-9_28.

PMID:
28986806
3.

Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.

Schandock F, Riber CF, Röcker A, Müller JA, Harms M, Gajda P, Zuwala K, Andersen AHF, Løvschall KB, Tolstrup M, Kreppel F, Münch J, Zelikin AN.

Adv Healthc Mater. 2017 Dec;6(23). doi: 10.1002/adhm.201700748. Epub 2017 Sep 25.

PMID:
28945945
4.

From Virus to vector to medicine: Foreword by guest editors.

Kreppel F, Ehrhardt A.

Virus Genes. 2017 Oct;53(5):673-674. doi: 10.1007/s11262-017-1503-6. No abstract available.

PMID:
28921483
5.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
6.

Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy.

Hagedorn C, Kreppel F.

Hum Gene Ther. 2017 Oct;28(10):820-832. doi: 10.1089/hum.2017.139. Review.

PMID:
28854810
7.

Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Jönsson F, Kreppel F.

Virus Genes. 2017 Oct;53(5):692-699. doi: 10.1007/s11262-017-1498-z. Epub 2017 Jul 28. Review.

PMID:
28755290
8.

TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

Cebula M, Riehn M, Hillebrand U, Kratzer RF, Kreppel F, Koutsoumpli G, Daemen T, Hauser H, Wirth D.

Mol Ther. 2017 Oct 4;25(10):2289-2298. doi: 10.1016/j.ymthe.2017.06.018. Epub 2017 Jul 14.

9.

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.

Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Müller P, Kreuzaler M, Lu M, Favre S, Kreppel F, Löhning M, Luther SA, Zippelius A, Merkler D, Pinschewer DD.

Nat Commun. 2017 May 26;8:15327. doi: 10.1038/ncomms15327.

10.

Covalent decoration of adenovirus vector capsids with the carbohydrate epitope αGal does not improve vector immunogenicity, but allows to study the in vivo fate of adenovirus immunocomplexes.

Kratzer RF, Espenlaub S, Hoffmeister A, Kron MW, Kreppel F.

PLoS One. 2017 May 4;12(5):e0176852. doi: 10.1371/journal.pone.0176852. eCollection 2017.

11.

Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.

Krutzke L, Prill JM, Engler T, Schmidt CQ, Xu Z, Byrnes AP, Simmet T, Kreppel F.

J Control Release. 2016 Aug 10;235:379-392. doi: 10.1016/j.jconrel.2016.06.022. Epub 2016 Jun 11.

12.

A Method for Visualization of Incoming Adenovirus Chromatin Complexes in Fixed and Living Cells.

Komatsu T, Dacheux D, Kreppel F, Nagata K, Wodrich H.

PLoS One. 2015 Sep 2;10(9):e0137102. doi: 10.1371/journal.pone.0137102. eCollection 2015.

13.

A molecular tweezer antagonizes seminal amyloids and HIV infection.

Lump E, Castellano LM, Meier C, Seeliger J, Erwin N, Sperlich B, Stürzel CM, Usmani S, Hammond RM, von Einem J, Gerold G, Kreppel F, Bravo-Rodriguez K, Pietschmann T, Holmes VM, Palesch D, Zirafi O, Weissman D, Sowislok A, Wettig B, Heid C, Kirchhoff F, Weil T, Klärner FG, Schrader T, Bitan G, Sanchez-Garcia E, Winter R, Shorter J, Münch J.

Elife. 2015 Aug 18;4. pii: e05397. doi: 10.7554/eLife.05397.

14.

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

Tober R, Banki Z, Egerer L, Muik A, Behmüller S, Kreppel F, Greczmiel U, Oxenius A, von Laer D, Kimpel J.

J Virol. 2014 May;88(9):4897-907. doi: 10.1128/JVI.03276-13. Epub 2014 Feb 19.

15.

Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo.

Prill JM, Subr V, Pasquarelli N, Engler T, Hoffmeister A, Kochanek S, Ulbrich K, Kreppel F.

PLoS One. 2014 Jan 27;9(1):e82716. doi: 10.1371/journal.pone.0082716. eCollection 2014.

16.

Production of high-capacity adenovirus vectors.

Kreppel F.

Methods Mol Biol. 2014;1089:211-29. doi: 10.1007/978-1-62703-679-5_15.

PMID:
24132488
17.

Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.

Saini C, Liani A, Curie T, Gos P, Kreppel F, Emmenegger Y, Bonacina L, Wolf JP, Poget YA, Franken P, Schibler U.

Genes Dev. 2013 Jul 1;27(13):1526-36. doi: 10.1101/gad.221374.113.

18.

Foamy virus-adenovirus hybrid vectors for gene therapy of the arthritides.

Weber C, Armbruster N, Scheller C, Kreppel F, Kochanek S, Rethwilm A, Steinert AF.

J Gene Med. 2013 Mar-Apr;15(3-4):155-67. doi: 10.1002/jgm.2705.

PMID:
23554302
19.

Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor.

Vetter A, Virdi KS, Espenlaub S, Rödl W, Wagner E, Holm PS, Scheu C, Kreppel F, Spitzweg C, Ogris M.

Mol Pharm. 2013 Feb 4;10(2):606-18. doi: 10.1021/mp300366f. Epub 2013 Jan 18.

PMID:
23281933
20.

Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro.

Laakkonen JP, Engler T, Romero IA, Weksler B, Couraud PO, Kreppel F, Kochanek S.

PLoS One. 2012;7(9):e45977. doi: 10.1371/journal.pone.0045977. Epub 2012 Sep 27.

Supplemental Content

Loading ...
Support Center